Echinocandin resistance due to simultaneous FKS mutation and increased cell wall chitin in a Candida albicans bloodstream isolate following brief exposure to caspofungin

Journal of Medical Microbiology

Volumn 61, Issue PART 9, 2012, Pages 1330-1334

  Imtiaz, Toufeeq ^a   Lee, Kathy K ^b   Munro, Carol A ^b   MacCallum, Donna M ^b   Shankland, Gillian S ^c   Johnson, Elizabeth M ^d   MacGregor, Mark S ^a   Bal, Abhijit M ^a  

^a CROSSHOUSE HOSPITAL   (United Kingdom)

^b UNIVERSITY OF ABERDEEN   (United Kingdom)

^c ROYAL HOSPITAL FOR SICK CHILDREN   (United Kingdom)

^d PUBLIC HEALTH ENGLAND   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; C REACTIVE PROTEIN; CASPOFUNGIN; CHITIN; CREATININE; ECHINOCANDIN; FLUCONAZOLE; GLUCAN SYNTHASE; PIPERACILLIN PLUS TAZOBACTAM; UREA;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIFUNGAL RESISTANCE; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CANDIDA ALBICANS; CANDIDEMIA; CASE REPORT; CELL WALL; CREATININE BLOOD LEVEL; FEMALE; GENE MUTATION; HEPATORENAL SYNDROME; HUMAN; LEUKOCYTOSIS; LOADING DRUG DOSE; MEDICAL HISTORY; MINIMUM INHIBITORY CONCENTRATION; NEUTROPHILIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; STAPHYLOCOCCUS AUREUS; UREA BLOOD LEVEL;

CANDIDA ALBICANS; CANDIDEMIA; CELL WALL; CHITIN; DRUG RESISTANCE, FUNGAL; ECHINOCANDINS; FEMALE; FUNGAL PROTEINS; GLUCOSYLTRANSFERASES; HUMANS; MIDDLE AGED; MUTATION;

EID: 84865187086     PISSN: 00222615     EISSN: None     Source Type: Journal    
DOI: 10.1099/jmm.0.045047-0     Document Type: Article

References (17)

1. Ben-Ami, R., Garcia-Effron, G., Lewis, R. E., Gamarra, S., Leventakos, K., Perlin, D. S. & Kontoyiannis, D. P. (2011). Fitness and virulence costs of Candida albicans FKS1 hot spot mutations associated with echinocandin resistance. J Infect Dis 204, 626-635.
2. Chalmers, C. M. & Bal, A. M. (2011). Management of fungal infections in the intensive care unit: a survey of UK practice. Br J Anaesth 106, 827-831.
3. Costa-de-Oliveira, S., Marcos Miranda, I., Silva, R. M., Pinto E Silva, A., Rocha, R., Amorim, A., Gonç alves Rodrigues, A. & Pina-Vaz, C. (2011). FKS2 mutations associated with decreased echinocandin susceptibility of Candida glabrata following anidulafungin therapy. Antimicrob Agents Chemother 55, 1312-1314.
4. Dannaoui, E., Desnos-Ollivier, M., Garcia-Hermoso, D., Grenouillet, F., Cassaing, S., Baixench, M. T., Bretagne, S., Dromer, F., Lortholary, O. & French Mycoses Study Group (2012). Candida spp. with acquired echinocandin resistance, France, 2004-2010. Emerg Infect Dis 18, 86-90.
5. Garcia-Effron, G., Park, S. & Perlin, D. S. (2009). Correlating echinocandin MIC and kinetic inhibition of fks1 mutant glucan synthases for Candida albicans: implications for interpretive breakpoints. Antimicrob Agents Chemother 53, 112-122.
6. Garcia-Effron, G., Chua, D. J., Tomada, J. R., DiPersio, J., Perlin, D. S., Ghannoum, M. & Bonilla, H. (2010). Novel FKS mutations associated with echinocandin resistance in Candida species. Antimicrob Agents Chemother 54, 2225-2227.
7. Kofteridis, D. P., Lewis, R. E. & Kontoyiannis, D. P. (2010). Caspofungin-non-susceptible Candida isolates in cancer patients. J Antimicrob Chemother 65, 293-295.
8. Lee, K. K., Maccallum, D. M., Jacobsen, M. D., Walker, L. A., Odds, F. C., Gow, N. A. & Munro, C. A. (2012). Elevated cell wall chitin in Candida albicans confers echinocandin resistance in vivo. Antimicrob Agents Chemother 56, 208-217.
9. Pappas, P. G., Kauffman, C. A., Andes, D., Benjamin, D. K., Jr, Calandra, T. F., Edwards, J. E., Jr, Filler, S. G., Fisher, J. F., Kullberg, B. J. & other authors (2009). Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 48, 503-535.
10. Park, S., Kelly, R., Kahn, J. N., Robles, J., Hsu, M. J., Register, E., Li, W., Vyas, V., Fan, H. & other authors (2005). Specific substitutions in the echinocandin target Fks1p account for reduced susceptibility of rare laboratory and clinical Candida sp. isolates. Antimicrob Agents Chemother 49, 3264-3273.
11. Parkins, M. D., Sabuda, D. M., Elsayed, S. & Laupland, K. B. (2007). Adequacy of empirical antifungal therapy and effect on outcome among patients with invasive Candida species infections. J Antimicrob Chemother 60, 613-618.
12. Pfeiffer, C. D., Garcia-Effron, G., Zaas, A. K., Perfect, J. R., Perlin, D. S. & Alexander, B. D. (2010). Breakthrough invasive candidiasis in patients on micafungin. J Clin Microbiol 48, 2373-2380.
13. Ruhnke, M., Rickerts, V., Cornely, O. A., Buchheidt, D., Glöckner, A., Heinz, W., Höhl, R., Horré, R., Karthaus, M. & other authors (2011). Diagnosis and therapy of Candida infections: joint recommendations of the German Speaking Mycological Society and the Paul-Ehrlich-Society for Chemotherapy. Mycoses 54, 279-310.
14. Schelenz, S., Barnes, R. A., Kibbler, C. C., Jones, B. L. & Denning, D. W. (2009). Standards of care for patients with invasive fungal infections within the United Kingdom: a national audit. J Infect 58, 145-153.
15. Schuster, M. G., Edwards, J. E., Jr, Sobel, J. D., Darouiche, R. O., Karchmer, A. W., Hadley, S., Slotman, G., Panzer, H., Biswas, P. & Rex, J. H. (2008). Empirical fluconazole versus placebo for intensive care unit patients: a randomized trial. Ann Intern Med 149, 83-90.
16. Walker, L. A., Munro, C. A., de Bruijn, I., Lenardon, M. D., McKinnon, A. & Gow, N. A. (2008). Stimulation of chitin synthesis rescues Candida albicans from echinocandins. PLoS Pathog 4, e1000040.
17. Walker, L. A., Gow, N. A. & Munro, C. A. (2010). Fungal echinocandin resistance. Fungal Genet Biol 47, 117-126.